Key Market Indicator:
Stock market news: In short news style a la Twitter/X. Everything that is relevant - at a glance. The entry page for the informed investor. Compact, worth knowing and always up to date. Directly from the IR departments of the companies.
DE0006632003
Wed, 25.10.2023
MorphoSys AG
Publication of an inside information according to Article 17 para. 1 of the Regulation (EU) No. 596/2014
Planegg/Munich, Germany, October 25, 2023
Ad hoc: MorphoSys AG Reports Preliminary Q3 2023 Monjuvi U.S. Sales and Gross Margin, and Updates Financial Guidance for 2023
Preliminary Q3 2023 Monjuvi U.S. net product sales of US$ 23.4 [ … ]
Tue, 12.09.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, September 12, 2023
MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer
Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company’s third clinical program to receive Fast Track designation
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced tha [ … ]
Wed, 09.08.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, August 9, 2023
MorphoSys AG Reports Second Quarter and First Half 2023 Financial Results
Monjuvi® U.S. net product sales of US$ 23.6 million (€ 21.7 million) for the second quarter of 2023
Enrollment of Phase 3 MANIFEST-2 study of pelabresib in first-line myelofibrosis is complete, with topline data expec [ … ]
Thu, 03.08.2023
MorphoSys AG
Conference Call Alert
Planegg/Munich, Germany, August 03, 2023
Invitation to MorphoSys’ Second Quarter and First Half 2023 Financial Results Conference Call on August 10, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will publish its results for the second quarter and first half 2023 on August 09, 2023, at 10:00 pm CEST (09:00 pm BST; 04:00 pm E [ … ]
Wed, 14.06.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, June 14, 2023
MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will host a virtual investor event on Wednesday, June 21, at 9:00 a.m. EDT / 3:00 p.m. CEST.
During the event, Jean-Paul Kress, M.D., MorphoSys’ Chi [ … ]
Wed, 14.06.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, June 14, 2023
MorphoSys to Host Virtual Investor Call with Key Opinion Leaders Focused on Pelabresib on June 21, 2023
MorphoSys AG (FSE: MOR; NASDAQ: MOR) will host a virtual investor event on Wednesday, June 21, at 9:00 a.m. EDT / 3:00 p.m. CEST.
During the event, Jean-Paul Kress, M.D., MorphoSys’ Chi [ … ]
Wed, 17.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 17, 2023
MorphoSys AG Reports Outcome of Annual General Meeting 2023
All Proposed Resolutions Approved
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera [ … ]
Wed, 17.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 17, 2023
MorphoSys AG Reports Outcome of Annual General Meeting 2023
All Proposed Resolutions Approved
MorphoSys AG (FSE: MOR; NASDAQ: MOR) announced today that its shareholders approved all resolutions proposed by the Company´s Management and Supervisory Boards at the Company´s virtual Annual Genera [ … ]
Thu, 11.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 11, 2023
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the latest data on multiple pipeline therapies will be presented during the American Society of Clinical Oncology (ASCO [ … ]
Thu, 11.05.2023
MorphoSys AG
Media Release
Planegg/Munich, Germany, May 11, 2023
MorphoSys Highlights Potential of Its Mid- to Late-Stage Oncology Pipeline at 2023 ASCO and EHA Annual Meetings
MorphoSys AG (FSE: MOR; NASDAQ: MOR) today announced that the latest data on multiple pipeline therapies will be presented during the American Society of Clinical Oncology (ASCO [ … ]